BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19048253)

  • 1. Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma.
    Gong Y; Ren L; Zhou L; Zhu J; Huang M; Zhou X; Wang J; Lu Y; Hou M; Wei Y
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):327-33. PubMed ID: 19048253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.
    Cao W; Xu C; Lou G; Jiang J; Zhao S; Geng M; Xi W; Li H; Jin Y
    Jpn J Clin Oncol; 2009 Sep; 39(9):582-7. PubMed ID: 19509000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus.
    Zhang X; Shen L; Li J; Li Y; Li J; Jin M
    Am J Clin Oncol; 2008 Feb; 31(1):29-33. PubMed ID: 18376224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
    Zhang XD; Shen L; Li J; Li Y; Li J; Zhang XT; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):474-7. PubMed ID: 17974288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
    Fan QX; Wang R; Lu P; Zhao YF; Lu TY; Han JW; Wang JS; Luo SX; Lu SP; Wang GJ; Geng L; Zhang MZ; Ma ZY; Song M; Wu XA; Chen XB; Jiao ZM; Wang RL
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):937-9. PubMed ID: 19173998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
    Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus].
    Huang J; Cai RG; Meng PJ; Zhang MJ; Cui CX; Yang L; Chu DT; Sun Y; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):753-5. PubMed ID: 15733398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
    Sato Y; Takayama T; Sagawa T; Okamoto T; Miyanishi K; Sato T; Araki H; Iyama S; Abe S; Murase K; Takimoto R; Nagakura H; Hareyama M; Kato J; Niitsu Y
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):570-6. PubMed ID: 16463059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer].
    Hirao M; Fujitani K; Tsujinaka T
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):53-6. PubMed ID: 15675582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
    Hirose T; Sugiyama T; Kusumoto S; Shirai T; Nakashima M; Yamaoka T; Okuda K; Ogura K; Ohnishi T; Ohmori T; Adachi M
    Anticancer Res; 2009 May; 29(5):1733-8. PubMed ID: 19443395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Kaechele V; Moehler M; Lutz MP; von Wichert G; Eisele M; Klaus J; Galle PR; Adler G; Seufferlein T
    Cancer Chemother Pharmacol; 2010 May; 66(1):191-5. PubMed ID: 20354701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma.
    Sekine I; Nokihara H; Horiike A; Yamamoto N; Kunitoh H; Ohe Y; Tamura T; Kodama T; Saijo N
    Br J Cancer; 2004 Mar; 90(6):1125-8. PubMed ID: 15026789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II clinical trial of home-produced Nedaplatin in treating advanced esophageal carcinoma].
    Xu RH; Shi YX; Guan ZZ; Jiang WQ; Huang H; Ma ZY; Wang JH; Hu XH; Xie WM; Li XG; Liu YL; Pan LX; Dai AD; Zhuang W; Zhang C
    Ai Zheng; 2006 Dec; 25(12):1565-8. PubMed ID: 17166388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas.
    Kato H; Fukuchi M; Manda R; Nakajima M; Miyazaki T; Sohda M; Masuda N; Fukai Y; Tsukada K; Kuwano H
    Anticancer Res; 2003; 23(4):3493-8. PubMed ID: 12926096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study.
    Hsu FM; Lin CC; Lee JM; Chang YL; Hsu CH; Tsai YC; Lee YC; Cheng JC
    J Surg Oncol; 2008 Jul; 98(1):34-41. PubMed ID: 18449912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
    Miyazaki T; Ojima H; Fukuchi M; Sakai M; Sohda M; Tanaka N; Suzuki S; Ieta K; Saito K; Sano A; Yokobori T; Inose T; Nakajima M; Kato H; Kuwano H
    Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
    Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
    Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
    Lin CC; Yeh KH; Yang CH; Hsu C; Tsai YC; Hsu WL; Cheng AL; Hsu CH
    Anticancer Drugs; 2007 Jul; 18(6):703-8. PubMed ID: 17762400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.